Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity

Figure 4

Tumor response after 5 cycles of trabectedin/irinotecan, patient with synovial sarcoma.

(a) PET-MRT showing index lesion before start of treatment

(b) PET-MRT showing index lesion after 5 cycles of treatment

(c) CT-Thorax showing index lesion before start of treatment

(d) CT-Thorax showing index lesion after 5 cycles of treatment